**Supplementary Figure 1.** Seroconversion rate after the 1st and 2nd vaccine dose of mRNA vaccine in (A) patients with systemic lupus erythematosus based on double-stranded DNA status; (B) patients with systemic lupus erythematosus based on complement C3c status; (C) patients with systemic autoimmune rheumatic disease based on the presence or absence of comorbidities. dsDNA: double-stranded DNA; C3c: proteolytic fragment of complement component 3.
Supplementary Figure 2. Anti-SARS-CoV-2 S antibody levels between the healthy control group (HC) and patients with systemic autoimmune rheumatic disease treated with mono- or combination therapies. y axis: 0-0.1: linear scale, 0.1-10000: log10 scale.
**Supplementary Figure 3.** Anti-SARS-Cov-2 S antibody levels between the healthy control group (HC) and patients with systemic lupus erythematosus treated with mono- or combination therapies. y axis: 0-0.1: linear scale, 0.1-10000: log10 scale.
Supplementary Figure 4. Anti-SARS-CoV-2 S antibody levels after the 1st and 2nd vaccine dose of mRNA vaccine in (A) patients with systemic lupus erythematosus based on double-stranded DNA status; (B) patients with systemic lupus erythematosus based on complement C3c status; (C) patients with systemic autoimmune rheumatic disease based on the presence or absence of comorbidities. y axis: 0-0.1: linear scale, 0.1-10000: log10 scale. dsDNA: double-stranded DNA; C3c: proteolytic fragment of complement component 3.
Supplementary Figure 5. Anti-SARS-Cov-2 S antibody levels between the healthy control group after 2nd vaccine dose and patients according to individual medications in mono- and/or combination therapy; AZA: azathioprine; GC: glucocorticoid; HC: healthy control; HCO: hydroxychloroquine; MMF: mycophenolate; MTX: methotrexate; y axis: 0-0.1: linear scale, 0.1-10000: log10 scale.